LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS

Similar documents
MEDICINES CONTROL COUNCIL

UPDATE: Regulatory Framework for Medical Devices in South Africa. SAMED Annual Conference. 14 June 2018 Jerry Molokwane

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL

ZAMBIA MEDICINES REGULATORY AUTHORITY EMPLOYMENT OPPORTUNITY

REPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA

MEDICINES CONTROL COUNCIL

Legal limitations for nurse prescribers: a focus on dispensing. Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences

NAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES

Feedback on SADC Workshop of Industry & Regulators. Luther Gwaza PhD Consultant

Post Market Surveillance Requirements. SAMED Regulatory Conference 2 December 2015

MEDICINES CONTROL COUNCIL

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI

Compounded Sterile Preparations Pharmacy Content Outline May 2018

MEDICAL DEVICES SECTOR

OUTSOURCING SURVEY. This year we had 315 industry professionals respond

EMA Inspection Site perspective

SADC Collaborative Medicines Registration Initiative (Zazibona)

MEDICINES CONTROL COUNCIL

The registration department at Kuwait Drug and Food Control Administration (KDFCA) monitors and

Drug and Medical Device Registration FAQ

Take a Course of Action.

Trends in the development of regulatory systems by the example of ICH countries

Definitions: In this chapter, unless the context or subject matter otherwise requires:

MEDICINES CONTROL COUNCIL

Dr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015

ICH Regulators Forum. Dr Peter Arlett EU

AC291 Special Inspection Agencies ACCREDITATION CRITERIA FOR IBC SPECIAL INSPECTION AGENCIES AC291

SUMMARY OF THE INDUSTRY TASK GROUP MEETING HELD AT 08:00 ON 23 JUNE 2015 IN THE CIVITAS BUILDING

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

MEDICINES CONTROL COUNCIL

SOP Title: Reporting Adverse Events and New Safety Information

Procedures and Conditions of Building Consent Authority Accreditation

Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) Botswana

Report on SAPC HOPS Meeting 5 April The SAPC met with Heads of Pharmaceutical Services from both the public and private sectors.

MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC

Authorized Personnel to Review

Mix of civil law and common law. Official law database Ministry for justice, culture and local government of Malta

SADC Collaborative Medicines Registration Process (ZAZIBONA) Farai Masekela 13 April 2016

Guidance for Industry

Guidance for registered pharmacies preparing unlicensed medicines

HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA

Regulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center

Arizona Department of Health Services Licensing and CMS Deficient Practices

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines

PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS

MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review

GUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS

International Pharmaceutical Federation Fédération internationale pharmaceutique. Standards for Quality of Pharmacy Services

Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

AN ACT. Be it enacted by the General Assembly of the State of Ohio:

NEW JERSEY. Downloaded January 2011

PHARMACITS COUNCIL OF NIGERIA ACT (1992 No. 91) REGISTRATION OF PHARMACEUTICAL PREMISES REGULATIONS, 2005.

...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS

IAF Mandatory Document for the Application of ISO/IEC in Medical Device Quality Management Systems (ISO 13485)

The Accredited Drug Dispensing Outlet (ADDO) Model in Tanzania

Postmarketing Drug Safety and Inspection Readiness

Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1

Procedures and Conditions of GLP Registration

DECEMBER 6, 2016 MEDICAL ASSISTANCE IN DYING GUIDANCE FOR PHARMACISTS AND PHARMACY TECHNICIANS

Understanding the Pharmacy and Drug Act amendments and mail order pharmacy licensing

Connie Hoy October 2013

The European network evaluation of the PHAR QA framework of competences for...

Registration of a new pharmacy premises

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

MINIMUM CRITERIA FOR REACH AND CLP INSPECTIONS 1

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

Remediation, Resolution and Outcomes

A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program

The South African Pharmacy Council An introduction to our Legal Team

Regulatory Conference: KEY TAKE- AWAYS. Engela Dedwith, Eli Lilly

FDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations

Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

ORGANIZATION OF AMERICAN STATES

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. House Bill 2028 SUMMARY

BIMO Program Update an operational perspective

Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit

Building Consent Authority Accreditation - Procedures and Conditions

Trial Management: Trial Master Files and Investigator Site Files

An Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule

managing or activities.

CDER Small Business and Industry Assistance (SBIA)

European Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS

Clinical Trial Quality Assurance Common Findings

EHR] A INSPECTION REPORT. Guy s Hospital Pharmacy St Thomas Street London SE1 9RT. Safeguarding public health

National Health Insurance. Sham Moodley BSc(UCD-Ire),BPharm(UKZN),PDM(HIV/AIDS),MPhil(HIV/AIDS)(SU) F

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

Regulatory Inspections

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) ANGOLA

H 5497 S T A T E O F R H O D E I S L A N D

Towards Quality Care for Patients. National Core Standards for Health Establishments in South Africa Abridged version

Update on FDA-EMA QbD Pilot

SOUTH AFRICAN NURSING COUNCIL

2018 UPDATES BUREAU OF HUMAN SERVICES LICENSING

HCA 302 Module 5 Lecture Notes The Pharmaceutical Industry and Health Care Workforce

NATIONAL MEDICINAL PRODUCTS POLICY 2013

Transcription:

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH

Outline Introduction Appointment of Council Organization SAHPRA Legislative update: Medical Devices, IVDs, API, CAMS Inspectorate: Standards of submissions and guidance for Improvement Institute of Regulatory Science (IRS)

Introduction Regulation and control of medicines is not an option but an imperative for national health programs The challenge is to have the necessary policy, objectives and the legislative provision and adequate and appropriate human, financial, technical and physical resources supported by appropriate SOPs and policy guidelines

Policy Framework Health Objectives of the National Drug Policy Availability and accessibility of Essential Medicines to all citizens Treatment Guidelines for Health Personnel (EDL) Safety, Efficacy and Quality of medicines through evaluation, testing, registration and post-registration surveillance Good Dispensing and Prescribing Practices Rational Use of medicines Individual responsibility for Health, Preventive Care and Informed Decision Making

Legislative Framework Medicines and Related Substances Act, 1965 (Act 101 of 1965) Medicines Control Council Registrar and Secretariat Regulation and Control of Medicines, scheduled substances, Medical Devices Licensing of Manufacturing, Storage and Distribution Facilities

Elements of Act 101 of 1965 Registration of Medicines Establishment of MCC juristic entity Declaration of Commercial interest of members Control of medicines, scheduled substances, medical devices Prohibition of unregistered medicines Expedited registration of essential medicines Re-evaluation of medicines after 5 years Supply of more affordable medicines in certain cases Product labeling and consumer information Prohibition of sampling & bonusing Licensing of manufactures, wholesalers, distributors Licensing of persons who compound & dispense Generic substitution Pricing Committee Regulation of Clinical Trials Regulate purchase & sale of medicines by licensees Appeals Fees Regulation power of Minister

Medicines Control Council MCC established in terms of Act 101 of 1965 Council consists of not more than 24 members (expertise of 14 members is defined) appointed by the Minister of Health Chair & Vice-chair Office of the Registrar of Medicines Executive Committee Expert Committees Secretariat of the MCC Appointed by the Department of Health

Qualification of Council (Regulation 35) Medical Practitioner & Public health Medical Practitioner & Paediatrics Medical Practitioner & internal medicine Pharmacist & pharmaceutics and bioequivalence Veterinarian rep from DoA Agriculture Reg 35(a) Reg 35(a) Reg 35(a) Reg 35(f) Reg 35(j)

Qualification of Council (Regulation 35) Complementary medicines Biotechnology Pharmaceutical Chemistry Virology & microbiology Adverse Drug Reactions Pharmaceutical Chemistry Law Veterinary clinical pharmacology Clinical pharmacology Reg 35(k) Reg 35(e) Reg 35(c) Reg 35(h) Reg 35(c ) Reg 35(l) Reg 35(i) Reg 35(b)

Medicines Control Council Objectives and Functions Regulation in the public interest Quality, safety & efficacy of medicines (QSE) Appropriate prescribing information Efficient, effective, ethical evaluation & registration of medicines Transparent, fair, objective, timeous, and confidential decision-making Periodic reassessment & monitoring Adverse events & interactions monitoring Compliance with legislation inspections and audits Clinical trial regulation

Medicines Control Council & Expert Committees Office of the Registrar MEDICINES CONTROL COUNCIL Executive Committee Clinical Committee Clinical Trials Committee Scheduling Committee Pharmacovigilance Committee Pharmaceutical & Analytical Biological Committee Complementary Medicines African Traditional Meds Legal Committee Veterinary Clinical Committee

Office of the Registrar of Medicines Registrar and provision for 2 Deputy Registrars; Office serves as Executive Secretary to the Medicines Control Council; Provides administrative and technical support for the MCC and its Expert Committees; Manage staff and activities of the Secretariat - Chief Directorate within the Department of Health - Cluster: Pharmaceutical and Related Product Regulation & Management and also oversees Food and Radiation Control Directorates

Registrar of Medicines and Cluster Manager Assistant Directors Executive Assistants Directorate: Inspectorate & Law Enforcement Directorate: Medicines Evaluation & Research Directorate: Clinical Evaluation & Trials Directorate: Operations & Administration Deputy Director: Inspectorate Deputy Director: Pre-registration Deputy Director: Pre-registration Deputy Director: Operations and Administration Deputy Director: Licensing Deputy Director: Post-registration Deputy Director: Post-registration Registry Finance Logistics Deputy Director: Law Enforcement Deputy Director: Veterinary Deputy Director: Clinical Trials Council EDMS & ectd Deputy Director: Complementary Medicines Deputy Director: Section 21 Deputy Director: Biological Medicines Deputy Director: Pharmacovigilance

Interaction between MCC and DoH Minister of Health MCC Registrar Deputy Registrars DOH -Issue permits -Issue licence Cluster MRA MRA Staff Inspectorate National DOH Evaluators Committee Outsourced Services National Treasury Minister of Finance

South African Health Products Regulatory Authority (SAHPRA) Amendment to Medicines Act passed in 2008 establish new Authority (SAHPRA) to replace the MCC. Not implemented as yet. Amendment Bill (Bill 6 of 2014)in Parliament to address transition. SAHPRA = juristic entity, independent of NDoH, responsible to Minister & compliant with the Public Finance Management Act (PFMA). Board of SAHPRA have governance and fiduciary duties.

South African Health Products Regulatory Authority (SAHPRA) Board appoint Chief Executive Officer (CEO) CEO appoints Committees to assist with work of Authority Regulatory framework will include medicines, API s medical devices, IVD s. Authority registers medicine, Medical Devices and IVDs SAHPRA employ own staff and retain fees for services.

South African Health Products Regulatory Authority (SAHPRA) MINISTER SAHPRA Section 3A public entity Administrative Chief Financial Officer Executive Manager: Corporate Services BOARD CEO Regulatory Risk Audit Committee (PFMA) Technical Support (Executive Manager) Authorization Management Inspectorate And Regulatory Compliance Medicines Medical Devices and Diagnostics (Inc IVDs & Radiation Control) Complementary Medicines

Legislative update: Medical devices, IVDs, APIs, CAMS Regulations and Guidelines to control Medical Devices and IVDs Published Stakeholder comment Re publish for 1 month comment (post April 2015) Workshop with Stakeholders (May-June 2015) Publish for implementation

Legislative update: Medical devices, IVDs, APIs, CAMS Regulations to control CAMS (2014-2019) Proposed definition for CAMS (Nov 2014) Stakeholder comments Workshop 30 March 2015 Publication for Implementation Bill 6 of 2014: Section 22C(1)(b) to license API Importers Wholesalers Manufacturers

Inspectorate: Standards of submissions and Guidance

Inspectorate: Standards of submissions Implementing corrective actions without establishing the root cause for example: the powders in the production corridor has been cleaned with no investigation done to establish why there were powders Inadequate assessing of the effectiveness or impact of corrective actions

Inspectorate: Standards of submissions cont Lack of preventative measures to prevent recurrence of events for example: processes are improved, but personnel not trained on the new processes Implementing corrective actions without following adequate procedures for example: corrective actions are not implemented via change control

Inspectorate: Standards of submissions and guidance for Improvement cont Providing unreliable, unrealistic and misleading timelines for example: claiming completion with only a quote or an order, or only protocols have been drawn up and no results and reports, or equipment has been installed but not qualified, etc.

Inspectorate: Standards of submissions and guidance for Improvement Responses are not implemented for example: when a follow-up inspection is performed, CAPA s indicated in the responses are found not to be implemented Providing misleading responses for example: providing a picture as evidence for new pressure gauges to replace the non compliant ones, or to show it is calibrated, but only one was purchased and calibrated for the purpose of the response

Inspectorate: Standards of submissions and guidance for Improvement Rather than responding, MCC observations compared with other NRAs for example: we were inspected by the FDA last week, with no, or no critical observations or the TGA did not require for us to implement quality control separate from production areas and We believe that the alleged deficiencies identified in the report and the subsequent classification thereof in Critical and Major Deficiencies is done in an arbitrary manner

Inspectorate: Standards of submissions cont The use of risk assessments to avoid compliance for example: using the fact that the products handled on the site is only S0 or complementary and therefore there is no need for all GMP requirements.

Inspectorate: Standards of submissions cont The use of delay tactics to provide responses on time for example: travelling at the moment, can only respond on return Inadequate or no supportive documents provided for example : SOP now exist, Information now available for inspection

Inspectorate: Standards of submissions cont Poor understanding of MCC processes for example: expecting a license to be issued immediately after the response was submitted

Inspectorate: Guidance for Improvement Guideline on How to Respond to a GMP or GWP Inspection Report was drafted To be discussed at the next Inspectorate P&A meeting to be held 31 March 2015 Anticipate to be published on the MCC website for industry to comment after the next MCC meeting

MCC/SAHPRA Guidance for improvement Establishment of Institute of Regulatory Science Within MCC/SAHPRA Virtual University for RSA, SADC, Africa Students: Regulatory staff from NRA, Industry etc Best practices from various universities, local and international

WORKING TOWARDS SAHPRA! MCC WEBSITE: www.mccza.com The Registrar of Medicines Private Bag X828 PRETORIA 0001 Tel: 012 395 8032 Fax: 012 395 8003